Version	Date
10/22/20	08

Clinical Study Status Report

Principal Investigator:

CLINICAL STUDY STATUS REPORT

Renewal/Continuing Review Request

Principal Investigator:

Study Title:						HAC N	umber:	
Current Approval Date	e:			Approval Te	erminates	: :		
Performance Site:]мсдні [□мсс [☐ Charlie N	Norwood VAN	мс І	Other:		
Indicate the current state	tus of the stu	dy:						
Not yet started								
Active, no huma	n subjects (sa	mples and ti	ssues only)					
Active, no huma	n subjects (ch	art review o	nly)					
Active, enrolling	g subjects*							
Active, treating s	subjects only							
Active, follow-u	p only							
Completed ** A incomplete, the study mus	•	•	l. If subjects	are in follow-	up, or if do	ata analysis	is	
*Per the federal regulations informed consent docume			•	~ .			ppy of the	
** If the study is in the for Advertisements must also	* *		CD and/or C	AD are not rec	quired for	approval.		

Version	Date
10/22/20	08

Clinical Study Status Report

HAC Number:	

Principal Investigator:

SECTION 2. SUBJECT INFORMATION

Cumulative Number of Subjects from the Beginning of the Protocol Approval:

Do not write in the shaded areas. If this form was completed before, then the numbers in the shaded areas below are the numbers that were previously reported to the HAC. Complete the "Subject Changes Since the Last Review" and the "New" columns.

NOTE: The sum of the numbers in "Withdrawn/Screen Failures", "Completed", and "Continuing" must equal the number "Consented".

	Prior	Subject Changes Since the Last Review	New Total
Specified by the Protocol/Contract			
Screened			
Consented			
Withdrawn/Screen			
Failures			
Completed			
Continuing			

If subjects were withdrawn during the time since the last review, please provide the following information (if additional space is needed, please attach an additional report). You are not required to report on screen failures.

Subject Study Identifier	Withdrawal Date	Reason for Withdrawal

SECTION 3

Equitable Selection of Subjects: Provide subject information since the last review.

1.	Number of male subjects	
1.	Trumber of male subjects	
2.	Number of female subjects	
3.	Number of African-American subjects	
4.	Number of Asian subjects	
5.	Number of Caucasian subjects	
6.	Number of Hispanic subjects	
7.	Number of subjects from other ethnic groups	
8.	Number of subjects considered as members of a vulnerable population as defined by HAC Policies and Procedures.	
9.	Number of non-veterans enrolled at VA, if applicable	

Version Date 10/22/2008

Clinical Study Status Report

HAC Number: _	Principal Investigator:
HAC Number:	

SECTION 4 - RISKS, BENEFITS, CONFLICTS OF INTEREST AND REQUIRED REPORTING

Please answer these questions as they pertain to the period from the last continuation approval (or the initial HAC approval, as applicable) of the study: If this question does not apply to your study, check "No".

Have any unanticipated problems (UAP) involving risks to subjects or others occurred? (If yes, and not already submitted to the HAC, submit the UAP with the HAC Form 113)	Yes *	□ No
Has the investigator reported all unexpected and related adverse events involving risks to subjects or others? (If yes, and not already submitted to the HAC, submit the URAE with the HAC Form 110)	Yes	□ No
Has the investigator reported all unexpected and related serious adverse events involving risks to subjects or others? (If yes, and not already submitted to the HAC, submit the URSAE with the HAC Form 110)	Yes	No No
Has any subject sought compensation for injury or complained about their participation in the study? (If yes, and not already submitted to the HAC, submit pertinent information with the HAC Form 113.)	Yes	No No
Has any recent relevant literature been published that relates to the study? (If yes, please submit a summary and/or a copy of the report (s))	Yes	No No
Have there been any interim findings? (If yes, and not already submitted to the HAC, submit pertinent information with the HAC Form 113.)	Yes	□ No
Are there any changes in the nature and/or degree of the risks or benefits, which may result from this research study? (If yes, explain in section 6. Attach additional pages as needed.)	Yes	No No
Have any issues of non-compliance occurred? (If yes and not submitted to the HAC, notify the HAC immediately via email at HAC@mcg.edu. NOTE: All issues of non-compliance must be reported to the HAC upon occurrence.)	Yes	No No
Have there been any changes in the conduct of the protocol that result in a conflict of interest for the investigator or research team members?	Yes	No No
Has there been any change in the risk to benefit ratio for the subjects enrolled in the protocol? (If yes, include this information in Section 6 Report of Study Progress.)	Yes	No No

Version Date 10/22/2008

Clinical Study Status Report

SECTION 5 ADDITIONAL REPORTS

SECTION 5 ADDITIONAL REPORTS			
If any amendments or other changes were submitted to the HAC, see the attached activity log and verify accuracy			
of data. Please provide any discrepancies to the HAC. This report is required for ALL studies, continuing or not.			
Please provide the following repo	rts (if applicable):		
IND Safety Report Sum	mary		
Multi-Center Trial Repo	rt		
I have reviewed the attached activ			
Yes they are correct and	no changes are needed		
No they are incorrect an	d the changes are submitted via the HAC Form 113		
SECTION 6 REQUIRED DOO	CUMENTS INCLUDED WITH THIS REQUEST FOR CONTINUING		
REVIEW/RENEWAL			
Yes No N/A	Current Informed Consent Document in use at the site, if applicable		
Yes No N/A	Current Children's Assent Document in use at the site, if applicable		
Yes No N/A	Current Parent/Guardian Informed Consent Document in use at the site, if applicable		
Yes No N/A	New Clean Version of the Informed Consent Document, if applicable		
Yes No N/A	New Clean Version of the Children's Assent Document, if applicable		
Yes No N/A	New Clean Version of the Parent/Guardian Informed Consent Document, if applicable		
Yes No N/A	Current Advertisements/Recruitment Materials, if applicable		
Yes No N/A	New Clean Version of the Advertisements/Recruitment Materials, if applicable		
Yes No N/A	Current Description of Research Proposal		
Yes No No N/A	Recent and Relevant Literature (by this research team or others)		
SECTION 7 REPORT OF ST	UDY PROGRESS		
	the study since the last review (initial or continuing) of study. Statements such as		
1 1 0 1	"No changes" are inadequate. Include information related to challenges with		
recruitment, payment to subjects, concerns about the research protocol, staffing changes, etc. Attach additional pages as			
needed.			

Version Date	Clinical Study Status Report	HAC Number: _	
10/22/2008			Principal Investigator:
_			
_			
SECTION 8			
If you are serving as an investiga	ator/sponsor for an IND/IDE. Have you met the regu	latory requirements for	
sponsors according to HAC Poli	et the regulatory requirements		
I have not met the regu	latory requirements		
Not Applicable			

SECTION 9 INVESTIGATOR CERTIFICATION STATEMENT

I certify that **any** changes to the protocol, including addition or deletion of study personnel, changes to the informed consent document (ICD) and/or children's assent document (CAD), study site, and when applicable, FDA Form 1572, were reported to the HAC within specified timelines. I assure the HAC that all unanticipated problems, serious or unexpected adverse events or issues of non-compliance were reported to the HAC within the specified timeline. I realize that as the Principal Investigator I am responsible for the conduct of this study and all personnel associated with it. I am also responsible for submitting this request to the HAC within the required timelines. I realize that all study related activity must stop on the approval expiration date if I have not submitted this required report within the required timelines.

Version Date 10/22/2008	Clinical Study Status Report	HAC Number:Principal Investigator:
Principal Investigator (Required)		
	Signature:	Date:

Version Date	Clinical Study Status Report	HAC Number:	
10/22/2008			Principal Investigator:

Version Date	Clinical Study Status Report	HAC Number:	
10/22/2008			Principal Investigator: